Multiple roles of Sonic Hedgehog in the developing human cortex are suggested by its widespread distribution

Fani Memi1,3 · Nada Zecevic1 · Nevena Radonjić2

Received: 29 September 2017 / Accepted: 25 January 2018 / Published online: 28 February 2018
© The Author(s) 2018. This article is an open access publication

Abstract
Sonic Hedgehog (Shh) plays an instrumental role in brain development, fine-tuning processes such as cell proliferation, patterning, and fate specification. Although, mutations in the SHH pathway in humans are associated with various neurodevelopmental disorders, ranging from holoprosencephaly to schizophrenia, its expression pattern in the developing human brain is not well established. We now determined the previously not reported wide expression of SHH in the human fetal cerebral cortex during most of the gestation period (10–40 gestational weeks). This spatiotemporal distribution puts Shh in a position to influence the fundamental processes involved in corticogenesis. SHH expression increased during development, shifting from progenitor cells in the proliferative zones to neurons, both glutamatergic and GABAergic, and astrocytes in upper cortical compartments. Importantly, the expression of its downstream effectors and complementary receptors revealed evolutionary differences in SHH-pathway gene expression between humans and rodents.

Keywords Cerebral cortex · Human fetal brain · Morphogen · SHH receptors

Introduction
Corticogenesis is a developmental process that requires coordination of the signaling pathways providing mitogenic signals and guiding the regulation of symmetric/asymmetric divisions of neuronal progenitors, positional information, differentiation signals, and a balance of excitation and inhibition in the cortex. Cortical development has been extensively studied in mice, and although it is considered to be generally well conserved in mammals, a number of changes and novelities have emerged during evolution that may underlie the biological basis for the higher cognitive and motor abilities that are specific to humans (Geschwind and Rakic 2013; Silbereis et al. 2016). Sonic Hedgehog (Shh) is a pleiotropic protein that plays a major role in most of the aforementioned processes during corticogenesis, including dorso-ventral patterning, the specification of interneurons and oligodendrocytes, as well as cortical circuitry formation (Fuccillo et al. 2006; Echelard et al. 1993; Ericson et al. 1995; Xu et al. 2005; Tekki-Kessaris et al. 2001; Harwell et al. 2012).

During mouse embryonic development, Shh is highly expressed in the ventral forebrain, where it plays a critical role in patterning during a specific developmental time window (embryonic days 9.5–12.5) (Xu et al. 2005; Fuccillo et al. 2004; Machold et al. 2003). Notably, changes in the concentration of Shh and the duration of Shh exposure influence the specification of different ventral progenitors and their neuronal progeny, which range from hypothalamic and striatal projection neurons to cortical and striatal interneurons (Maroof et al. 2013; Tyson et al. 2015). Despite the sparse expression of Shh in the mouse dorsal telencephalon (Dahmene et al. 2001), conditional inactivation of the Shh pathway leads to the defective proliferation of intermediate...
progenitor cells and to microcephaly (Komada et al. 2008). These results point to the concentration-dependent functions of this morphogen in both dorsal and ventral forebrain developments.

The significance of SHH in human brain development is illustrated by the dramatic consequences of SHH-pathway gene disruption, which include holoprosencephaly, seizure disorders, language or cognitive impairment, Down syndrome, hyperactivity, and schizophrenia (Heuvels et al. 2002; Nanni et al. 1999; Belloni et al. 1996; Odent et al. 1999; Santiago et al. 2006; Currier et al. 2012; Betcheva et al. 2013). Many of these conditions are the result of SHH haploinsufficiency, thus highlighting the importance of SHH gene dosage in humans (Chiang et al. 1996). Although in human embryos (Carnegie stages 12–16), the expression of SHH has been demonstrated ventrally, in the notochord, in the floorplate of the spinal cord, and in the hindbrain (Odent et al. 1999; Hajihosseini et al. 1996), there is a lack of information regarding the sources of SHH in the developing cerebral cortex.

A prerequisite for understanding the physiological role of SHH signaling during cortical development is the determination of its distribution and identification of its cellular sources in the prenatal human cortex. Our initial results, obtained in vitro, showed that at mid-gestation (around 20 gestational weeks, gw), SHH is expressed by radial glia cells (RGCs) and that treatment with exogenous SHH favours the termination of its distribution and identification of its cellular sources in the prenatal human cortex. Our initial results, obtained in vitro, showed that at mid-gestation (around 20 gestational weeks, gw), SHH is expressed by radial glia cells (RGCs) and that treatment with exogenous SHH favours the termination of its distribution and identification of its cellular sources in the prenatal human cortex.

In situ hybridization

The human full-coding sequences (CDS) for GLI1, GLI2, GLI3, and PTCH 1 were purchased from Dharmaco. The human SHH CDS was a gift from Cliff Tabin (Marigo et al. 1995) (pBS hShh CT#401 Addgene # 13996). For the SMO, BOC, GAS1, and CDON probes, cDNAs from human fetal brain (18 gw) were used as templates. The riboprobes were generated from a PCR fragment containing the transcription promoter sites T3/T7/SP6 (see Table S2), by in vitro transcription using digoxigenin (DIG)-UTP (Roche) as the label. ISH was performed as previously described (Radonjić et al. 2014). Briefly, cryo-sections (15 µm) were dried at room temperature (RT) for 2 h, fixed for 10 min with 4% paraformaldehyde (PFA), and washed twice in diethyl pyrocarbonate (DEPC)-treated phosphate buffer solution (PBS) before overnight incubation at 70 °C in hybridization buffer containing 1 × DEPC-treated “salts” (200 mM NaCl, 5 mM EDTA, 10 mM Tris, pH 7.5, 5 mM NaH2PO4·2H2O, 5 mM Na2HPO4; Sigma-Aldrich), 50% deionized formamide (Roche), 0.1 mg/mL of RNase-free yeast tRNA (Invitrogen, Carlsbad, CA, USA), 1 × Denhardts (RNase/DNase-free; Invitrogen), 10% dextran sulfate (Sigma-Aldrich) containing 100–500 ng/mL of digoxigenin (DIG)-labeled RNA probe. After hybridization, the sections were washed three times in a solution containing 50% formamide 1 × SSC (saline-sodium citrate, Invitrogen) and 0.1% Tween 20 (Sigma-Aldrich) at 65 °C, and twice at RT in 1 × MABT (20 mM maleic acid, 30 mM NaCl, 0.1% Tween 20; Sigma-Aldrich) before incubating in a solution containing 2% blocking reagent (Roche) and 10% heat-inactivated sheep serum in MABT, followed by overnight incubation in alkaline-phosphatase-conjugated anti-DIG antibody (1:1500; Roche).

**Materials and methods**

**Human fetal brain tissue**

Human fetal brains (n = 30) from 8 to 40 gw (gestational weeks correspond to postconceptional weeks; full term = 40 gw) (Table S1) were obtained from the Human Fetal Tissue Repository at the Albert Einstein College of Medicine (Bronx), Advanced Bioscience Resources (Alameda, CA), StemEx (Diamond Springs, CA, USA) and the joint MRC/Wellcome Trust-funded Human Developmental Biology Resource (http://www.hdbr.org) after legal abortions with appropriate maternal written consent and approval from the Ethics Committees of the participating institutions. All human materials were handled with special care and following all necessary requirements and regulations set by the Ethics Committee of the University of Connecticut and the Helsinki Declaration. Fetal age was estimated on the basis of weeks after last period, crown-rump length, and anatomical landmarks. In all studied fetuses, ultrasound and gross neuropathological examination were used to exclude those with brain pathology. The dissected tissues were fixed in 4% formaldehyde solution in 0.1 M phosphate buffer, cryoprotected by immersion in 30% sucrose, embedded in Tissue Tek (Sakura), frozen, and preserved in − 80 °C until needed. The tissues used for in situ hybridization (ISH) and immunohistochemistry were cut into 15-µm-thick sections.
Fast Red (Roche) was used for the fluorescent colorimetric detection of probe (FISH) by incubation in 100 mM Tris, pH 8.2, 400 mM NaCl containing Fast Red for 1–2 h at 37 °C. Alternatively, the TSA (tyramide signal amplification) kit (Perkinelmer) was used for FISH, in combination with anti-DIG-POD antibody (1:500, Roche). The sections were counterstained with bis-benzimide and cover-slipped using Fluormount G mounting medium. The specificity of the procedure was assessed with a probe corresponding to the sense strand of the respective genes.

Immunohistochemistry after ISH

After ISH, sections were subjected to antigen retrieval in 0.1 M citric acid, pH 9.0, and blocked in 10% normal goat serum (NGS)/PBS containing 0.2% Triton (PBST). Following overnight incubation with primary antibody (see Table S3 for details), the sections were thoroughly washed in PBST and incubated with secondary Alexa 488- or Alexa 555-conjugated antibodies (Life Technologies) for 2 h at RT. Alternatively, an ABC kit was used followed by DAB development. Nuclei were counterstained for 5 min at RT with the nuclear stain bis-benzimide (Sigma).

Quantification of immunolabeled cells

Immunolabeled sections were visualized with an Axioscope microscope (Zeiss) equipped with Axiovision software and photographed using a digital camera. Three samples (22–24 gw) were used for the quantifications presented in Figs. 4 and 5. Nuclear staining allowed the delineation of areas of interest (e.g., CP, SVZ, IZ, and GE). Ten images for each region of interest were observed at 40× magnification and the number of cells was counted using the Photoshop CS6 Count Tool. A descriptive analysis of the data was performed using the Excel Data analysis plug-in. The percentages of double-positive cells expressing SHH are presented together with the standard error of the mean (SEM).

Results

Distribution of SHH mRNA in the developing human forebrain

Detailed information on the spatial distribution of SHH in the human developing brain is lacking, in part due to the limited availability of tissue and the failure of most commercially available antibodies to label SHH. We thus used ISH against the human coding sequence of SHH to follow expression during 7 months of the human gestational period (8–40 gw; Table S1). The expression of SHH was highly dynamic, in accordance with the transcriptomics data available from the Allen Brain Institute (Fig. S1a, b). SHH expression in the fetal forebrain increased over the course of development and shifted from the proliferative ventricular (VZ) and subventricular zones (SVZ) (Fig. 1) to the overlying cortical layers (Fig. 2). At the earliest age studied (8–10 gw), Shh mRNA was predominantly restricted to the ventral forebrain, including the midline of the hypothalamus and thalamus, and to the emerging basal ganglia (Fig. 1a, e, f), in a similar pattern detected in the early embryonic mouse brain (Fig. S6a). By contrast, SHH mRNA was only weakly expressed dorsally, in the cortical plate (CP) and cortical VZ (Fig. 1a, b), a result confirmed by TSA-FISH (tyramide signal amplification) and the absence of a signal with the sense probe (Fig. 1g′ and S5). Furthermore, immunostaining with the rabbit monoclonal anti-SHH antibody (Farmer et al. 2016) revealed the definite presence of SHH protein in this area (Fig. 1g′′ and Fig. S1c–c′′). The proximal choroid plexus (ChP) was also positive for the SHH transcript and protein (Fig. 1h–h′). Notably, the levels of SHH were much higher in ChP cells than in the nearby VZ, as observed by the differences in signal intensity at the different exposure times/settings (Fig. S1c–c′′). Thus, it cannot be ruled out that the positive signal for the SHH protein in the cortical VZ reflected the uptake of ChP-secreted SHH by RGCs. However, SHH immunostaining in the cortical VZ appeared in more frontal sections that are much further from the ChP (not present in the same section), suggesting that SHH is produced locally.

Another source of SHH protein in the developing human brain at this stage is the meninges, which were strongly positive for SHH mRNA and protein. Within the meninges, SHH-expressing cells were those of smooth-muscle lineage, rather than fibroblasts, as demonstrated by co-localization with smooth-muscle actin but not vimentin antibody (Fig. 1j, k). Finally, SHH mRNA was detected in the endothelial cells of blood vessels in the GE stained for the endothelial cell marker PECAM (CD31), indicating that the developing vasculature is an additional source of SHH (Fig. S1d–d′′). Notably, endothelial cells in the ChP did not express SHH (Fig. 1i). Extracortically, SHH mRNA co-localized with SHH protein in the hypothalamic midline and retinal ganglion cells. In addition to validating the specificity of the antibody, this result provided insight into the range of SHH diffusion from its source (Fig. S1e–e′′, f–f′′).

In the subsequent stages of development (15–17 gw), the density and distribution of SHH transcripts increased considerably throughout the forebrain (Fig. 2a, b; Fig. S2a). Strong signal was detected not only in the cortical VZ/SVZ (Fig. 2a′′, b′; Fig. S2a), but also in the cortical plate (CP) (Fig. 2a′, b; Fig. S2a), whereas the signal in the intermediate zone (IZ) and subplate (SP) increased dramatically from 15 to 17 gw (Fig. 2a′, b′).

In the next stage of development, at mid-gestation (18–24 gw), SHH expression increased steadily in subpopulations of
cells in the expanded outer SVZ (oSVZ) (Figs. 3a, 6f), and in the IZ and SP, the zones through which neurons migrate (Figs. 2, 3a). At the same time, a very strong signal was present in cells located in the ganglionic eminence (GE) and hippocampus (Fig. 6j, S7c and Fig. S3). From 24 gw onwards, the SHH transcript signal in the cVZ decreased progressively, coinciding with a reduction in the size of these structures in late fetal development. This is the first study demonstrating SHH expression in the GE and cVZ in stages after 14 gw.

We then examined whether SHH transcripts were present uniformly along the rostro-caudal and dorso-ventral axis or formed a gradient in these regions of the human fetal cortex. ISH performed in sagittal sections of 15-gw forebrain showed that, although SHH expression appeared slightly higher in the rostral and caudal cortical areas than in the dorsal and ventral areas, the difference over the entire cortex was not significant (Fig. S2).

However, in later developmental stages (21–24 gw), SHH expression exhibited a high rostral to lower caudal gradient, as illustrated in coronal sections prepared from rostral (frontal), medial, and caudal (occipital) tissue blocks of the 23-gw fetal forebrain (Fig. 3a). Moreover, within each tissue block, SHH signal intensity was consistently stronger in dorsal than in ventral cortical areas (Fig. 3a).

In addition, cortical SHH expression exhibited regional differences, as illustrated in single coronal sections prepared through the level of the thalamus. The signal was always stronger above the insular region of the cortex, in the prospective somatosensory/motor cortices and possibly including Broca’s area (Fig. 3b:1–4), than in the ventrally
positioned temporal cortex (Fig. 3b:6–7). This pattern, which first emerged around 19 gw and became prominent at 22–24 gw, confirms the transcriptome data (Fig. S1a, b) that suggest higher expression in the dorsal than ventral cortex for this developmental stage.

These results revealed the complex pattern of SHH expression in the developing cortex and thus a possible role for SHH in cortical arealization during the second and third trimesters of gestation.

Characterization of SHH-expressing cells during mid-gestation

After establishing that SHH mRNA is expressed widely in fetal brain, we asked which cell types express SHH in the developing human cortex. The answer to this question is important, because it might indicate the roles played by SHH during development. We, therefore, subjected the fetal tissue sections to FISH followed by immunohistochemistry with cell-type-specific markers. Specifically, we asked whether during the late second trimester of gestation (20–24 gw), SHH transcripts are expressed by cortical progenitors, that is, RGCs, which are the predominant cell type in the proliferative VZ/SVZ. Using the RGCs markers Pax6, GFAP, and vimentin, we identified cells that co-express SHH mRNA as well as these markers (Fig. 4). Moreover, many of the SHH-expressing cells were proliferating, based on their co-labeling for the proliferation marker Ki67 (Fig. 4c). Quantification of the double-labeled cells showed that 89% (± 5.19 SEM, n = 3) of the Pax6-positive cells in the VZ expressed SHH transcripts, compared to 69% (± 6.6 SEM, n = 3) in the SVZ; thus, at this developmental stage the majority of RGCs in the proliferative zones produced SHH (Fig. 4e).

Since progenitors in the fetal cortex give rise mainly to glutamatergic neurons, SHH-expressing cells in cortical layers were probed with the glutamatergic cell marker Tbr1 (T-box Brain 1) to determine whether they belong to this neuronal population (Fig. 5a–a‴, b). From the total population of Tbr1+ cells in the subplate and the IZ, around 70% (n = 3) were positive for SHH (Fig. 5b). Thus, in addition to RGCs in the VZ/SVZ, a subpopulation of glutamatergic neurons in cortical layers is source of SHH. This finding was
confirmed using another marker for deep cortical layer neurons, CTIP2 (Fig. 5c). Two more general neuronal markers, Map2 and NeuN, were also co-expressed with SHH transcripts in a subpopulation of cortical neurons (Fig. 5d, e).

Co-labeling with GABA (Fig. 5f) or Gad65/67 (Fig. S4a, a’) suggested that at mid-gestation, cortical interneurons are less likely to express SHH transcript than glutamatergic neurons. Since not all SHH mRNA+ cells overlap with neuronal markers in higher cortical layers, we investigated whether non-neuronal populations in the cortex also express SHH transcript. Indeed, GFAP+ astrocytes in the IZ and SP/CP expressed SHH (Fig. 4d), but not oligodendrocytes or microglia labeled with Olig2 or Iba1, respectively (Fig. S4b, c). These data are consistent with a heterogeneous cell population producing Shh during mid-gestation, with the two main sources being RGCs and glutamatergic neurons.

**SHH-signaling pathway in the developing human cortex**

Despite the demonstration of the widespread expression of *SHH* in the developing human cortex, whether the classical *SHH* pathway was activated remained to be tested. Gli1 (GLI zinc finger transcription factor), a transcription factor activated by Shh-signaling, is the most sensitive and reliable read-out for this pathway as, unlike Gli2 and Gli3, it acts only as an activator (Bai et al. 2004). The presence of *GLI1* would, therefore, provide proof that the expressed SHH activates the signaling pathway in nearby cells. ISH using the human *GLI1* probes on sections from fetuses age 19–24 gw found that the *GLI1* transcript was expressed in the cortical VZ and CP/SP as well as in the GE in the GE (Fig. 6a–d). The intensity of the GE signal was much stronger, indicating a higher level of *SHH* expression, and hence SHH-signaling activity, in this area. *GLI3*, a transcription factor that acts as both a repressor and an activator of the Shh pathway (Ingham and McMahon 2001), was highly expressed in the cortical VZ, in the inner and outer SVZ (Fig. 6e, g–h), and in the hippocampus (Fig. 6i), confirming previously published transcriptomics data showing that *GLI3* is expressed by human RGCs (Pollen et al. 2015).

We then asked whether the SHH receptor PATCHED1 (PTCH1) is expressed in the vicinity of *SHH*-expressing cells. We tested tissues from fetuses of two gestational ages, early (10 gw), when cell proliferation, migration, and neurogenesis/fate specification are predominant, and later, at mid-gestation (19–24 gw), when additional processes such as axonal guidance and synaptogenesis occur. At 10 gw, *PTCH1* transcripts were non-detectable in the neocortex (Fig. 7b, b’), while expression was low in the VZ of the GE and in the thalamic and hypothalamic neuroepithelium, paralleling the spatiotemporal pattern of strong *SHH* expression in these ventral regions. At later stages (19–24 gw), when SHH expression increased in the cortex, *PTCH1* was seen in the cortical VZ, although at much lower levels than in ventral areas such as the GE or hypothalamus (Fig. 7h, h’). Immunostaining with PTCH1 antibody verified low- and high-level expression in the cortical VZ and GE, respectively (Fig. 7m, n). Co-labeling with GFAP also demonstrated the expression of this receptor by RGCs in the cortical VZ (Fig. 7m’). A weak *PTCH1* mRNA signal was detected in the dentate gyrus of the hippocampus (Fig. S3h).

In addition to Ptc1, three other membrane-associated proteins, the structurally related Boc (biregional Cdon-binding) and Cdon (cell-adhesion-molecule-related/down-regulated by oncogenes) proteins and the vertebrate-only Gas1 (growth-arrest-specific 1) protein, are thought to function as positive modulators of Shh signaling by enhancing the presentation of Shh to its receptor, Ptc1 (Tenzen et al. 2006; Allen et al. 2007; Martinelli and Fan 2007). Both Boc and Cdon promote Shh-dependent cell-fate specification and axon guidance (Tenzen et al. 2006; Okada et al. 2006), while Gas1 regulates the ventral specification of neural tube progenitors (Allen et al. 2007; Martinelli and Fan 2007) and CGNP (cerebellar granule neural progenitors) proliferation (Liu et al. 2001). Boc, Gas1, and Cdon are required for successful Shh signaling (Izzi et al. 2011). We found that *BOC* and *GAS1* were strongly expressed at 10 gw in cortical VZ and GE, whereas *CDON* was present only in the cortical VZ (Fig. 7c–e). *GAS1* was also expressed in the CP at this stage. The ChP cells, however, express only *BOC* at 10 gw (Fig. S8b). At later stages (19–24 gw), the expression of *BOC* and *CDON* was similar to that in earlier stages: high in the cortical VZ and SVZ and low in the CP/SP and GE (Fig. 7i–i’). *GAS1* expression in the CP was lower than at 10 gw, but remained high in the cortical VZ, oSVZ, and GE (Fig. 7k–k’). Finally, expression of the SHH signal transducer, *SMO* (smoothened) was weak in the 10-gw brain (Fig. 7f, f’), but increased in the 19-gw cortical VZ and in the CP (Fig. 7l–l’). *SMO* expression was also detected in the 10-gw ChP (Fig. S8a). Thus, in summary, all three receptors (*BOC*, *CDON*, and *GAS1*) were expressed in the VZ during early fetal development, pointing to their role in cell proliferation. *CDON* and *GAS1* were expressed at higher levels than *BOC* in the CP, suggesting their additional roles in cortical development.
Discussion

SHH is crucial for human brain development and changes in its signaling lead to distinct neuropathologies (Heussler et al. 2002; Nanni et al. 1999; Belloni et al. 1996; Odent et al. 1999; Santiago et al. 2006; Currier et al. 2012). Despite its importance, information on SHH expression profile in the developing human brain is still fragmentary. Here, we provided evidence of the expression of SHH and the transcription factors, and receptors necessary for its signaling, in specific cortical layers and cell types. Our study spans the course of most of the gestational period. The spatiotemporal
Fig. 5 Various subtypes of neurons express SHH in the 18–24 gw cortex.  

a–a‴ Co-labeling for SHH mRNA (red) and Tbr1 (green) reveals many postmitotic projection neurons across the SP and IZ expressing SHH.  

a, a‴ Single channels.  

b Percentage of Tbr1+ cells expressing SHH in the SP (70% ±7.6 SEM) and IZ (73% ±7.8 SEM) in 22–24-gw sections (n = 3).  

c–f SHH is expressed by neurons labeled with CTIP2 (c), MAP2 (d), NeuN (e), and GABA (f). Scale bars: a and a‴ 50 µm, a-inset 10 µm.
distribution suggests the involvement of SHH in diverse developmental processes in the human telencephalon, including cell proliferation and cell-fate specification in the VZ/SVZ, the subsequent migration of newly generated neurons, synaptogenesis, and circuit formation.

Our results agree with those of the previous studies (Odent et al. 1999), in which SHH mRNA was mostly detected in the ventral structures of the human brain during early stages (8–10 gw), with very low signal in the developing cerebral cortex. Given that a high concentration of SHH is known to induce patterning and cell-fate specification, whereas low levels regulate proliferation (Komada 2012; Komada et al. 2008; Wang et al. 2016a, b) this pattern of signal localization suggests that SHH regulates patterning and cell-fate specification in the human ventral forebrain and proliferation in the dorsal forebrain.

SHH transcripts were clearly detected in the cortical VZ/SVZ at 15 gw, which is consistent with our previous in vitro results showing that this morphogen is secreted by dorsal RGCs and induces their proliferation (Radonjic et al. 2016). The function of Shh in proliferation and regulation of symmetric/asymmetric divisions of intermediate progenitors in mice (Dave et al. 2011) points to a role as a mitogen in the human cortical proliferative zone. This role is probably maintained even past mid-gestation, since neurogenesis in humans continues up to 27 gw, later than previously known (Malik et al. 2013). Between 15 and 27 gw, SHH was also expressed in the IZ, SP, and CP, where the intensity of the signal increased over

---

Fig. 6 Components of the SHH-signaling pathway are expressed in the human fetal cortex at 22 gw. a, b ISH reveals the cortical expression of GLI1 (CP and VZ), indicative of SHH-signaling activity in these areas. c, d Strong GLI1 expression in the GE suggests higher levels of SHH activity ventrally. e, f GLI3 and SHH transcripts show similar high-density signals in the VZ and oSVZ. g On higher magnification, GLI3+ cells in the oSVZ resemble RGCs and are more numerous than in the VZ. h, i j Comparison of the GLI3 and SHH expression patterns in adjacent coronal sections at the level of the hippocampus (Hipp) of the 22 gw fetal brain. Scale bars: f 500 µm, g 50 µm, g - inset 15 µm, j 1 mm
time. Furthermore, we observed robust inter-regional and areal differences in the expression of \textit{SHH} during mid-to-late gestation in fetal neocortex. Although it is difficult to interpret this spatiotemporal expression pattern, these differences most likely have biological origin and they are not due to tissue quality or other variation as observed in all cases studied. The \textit{SHH}-positive cells in developing cortical layers were mostly neurons expressing Map2 or NeuN, with a subpopulation expressing glutamatergic markers (Tbr1 or CTIP2), as previously reported for the early postnatal mouse brain (Harwell et al. 2012). The \textit{SHH} transcript was also identified in a subpopulation of GABAergic cells, in accordance with the results of a single study in mouse (Komada et al. 2008). Given that Shh in mice plays a role in neuronal migration, axonal guidance (Fuccillo et al. 2006; Baudoin et al. 2012; Bourikas et al. 2005; Charron et al. 2003; Yam et al. 2009), and synaptic connectivity (Harwell et al. 2012), it is likely that it has similar functions in the developing human fetal neocortex. Moreover, the finding that GFAP-labeled astrocytes in the upper IZ, SP, and CP

Fig. 7 Expression of \textit{SHH} receptors in the fetal human brain at 10 and 19 gw. a–a’’ ISH for \textit{SHH} on a coronal section from a 10-gw brain, as a reference for all \textit{SHH} receptors in sections from the same fetus. Higher magnification of the boxed areas in (a): a’ cortex, a” cVZ. Weak signal is detected in the cortical VZ and GE. b–b” ISH for \textit{PTCH1} receptor reveals very low expression in the VZ (b”). \textit{BOC} expression is much more prominent along the cortical VZ and GE VZ (c–c”), whereas \textit{CDON} expression is restricted to the cortical VZ (d–d”). \textit{GAS1} is the only receptor expressed in both the VZ and CP, in addition to the GE (e–e”). \textit{SMOOTHENED} (SMO) is hardly detected in the VZ at this stage (f–f”). g–l” ISH for \textit{SHH} and all its receptors in contiguous sections of 19-gw brain. Two areas are presented for each gene: CP and VZ/SVZ. m Co-staining of 22-gw brain with Patched1 and GFAP antibodies shows that RGCs in the cortical VZ express this receptor. m’ Higher magnification of the boxed area in (m). n Patch1 immunoreaction in the same section reveals a strong expression in the GE. a 1 mm, a’ 150 µm, a” 25 µm
were positive for SHH suggests a role in numerous processes in which astrocytes are involved, such as synapse formation and synaptic plasticity (Farmer et al. 2016; Eroglu and Barres 2010) as well as the formation and maintenance of the blood–brain barrier (BBB). Indeed, recent work demonstrated that Hedgehog signaling promoted the formation and integrity of the BBB as well as the immune quiescence of the central nervous system (Alvarez et al. 2011). Microglia and oligodendrocytes were negative for SHH, but Olig2+ cells were found in close proximity to SHH-expressing cells, which correlates well with our previous in vitro study showing that SHH promotes the generation and maintenance of forebrain Olig2 progenitors (Ortega et al. 2013).

Our finding of GLI1 in the fetal cortical VZ and CP suggests active SHH signaling in the developing human cortex. This result is in line with our previous demonstration of functional SHH signaling in cortical RGCs in vitro, as indicated by the increased levels of GLI1 and PTCH1 after SHH treatment (Radonjic et al. 2016). In the present study, we provided evidence of PTCH1 (protein) as well as BOC, GAS1, and CDON expression in the human RGCs of the cortical VZ, which suggest an autocrine function for SHH in these progenitors. The role of these receptors has not been studied in cortical development, but they are known as positive modulators of Shh signaling in mice, in both cell proliferation in the cerebellum (Liu et al. 2001; Izzi et al. 2011) and cell-fate specification in neural tube progenitors (Allen et al. 2007; Martinelli and Fan 2007). A recent study has shown that Boc, Cdon, and Gas1 are necessary components of the Shh receptor complex and essential in Shh signal transduction in vertebrates (Izzi et al. 2011). Their strong expression in the human cortical VZ in association with the low-level expression of SHH and PTCH1 during early stages (10 gw) suggests that they could act as enhancers of SHH signaling. Impaired function of BOC, CDON, and GAS1 appears to underlie holoprosencephaly, both in humans (Clement et al. 2007; Ribeiro et al. 2010; Pineda-Alvarez et al. 2012; Bae et al. 2011) and in mice (Seppala et al. 2007; Zhang et al. 2006; McLellan et al. 2008). Interestingly, we found that BOC is strongly expressed in the human, but not in the mouse cortical VZ (Fig. S6, brainatlas.org), suggesting a species-specific difference. Indeed, comparative epigenetic profiling of human, monkey, and mouse brain tissue identified epigenetic gains (promoters and enhancers with gained activity) in genes involved in human corticogenesis, including BOC, SHH, NKX2.1, PTCH1, and GLI3 (Reilly et al. 2015).

Recent studies have suggested that the transcriptional programs associated with interneuron development in human are very similar in the GE and cortical VZ (Miller et al. 2014), which points to a role for SHH in interneuron fate specification, in addition to cell proliferation, in the cortical VZ. Indeed, our previous in vitro results show that SHH affects the commitment of some cortical RGCs to interneuronal fate (Radonjic et al. 2016). This points to the need for a better understanding of the origin and development of human cortical interneurons (Radonjic et al. 2014; Alzu’bi et al. 2017; Clowry et al. 2010). Such studies are likely to provide important insights into the pathogenesis of human neuropsychiatric disorders such as schizophrenia, in which dysfunction of GABAergic interneurons has been implicated (Benes and Berretta 2001; Guidotti et al. 2005; Lewis et al. 2005; Selemon and Zeccevic 2015).

In conclusion, the present study fills the gap in our knowledge about the presence of SHH in the developing human cortex which may enhance our understanding of human corticogenesis and the pathologies associated with defective SHH signaling.

Acknowledgements This work was supported by NIH Grants 2R01NS041489 and Subcontract 5R01DA023999-07(NZ). Human fetal tissue was procured from Advanced Bioscience Resources (ABR, Alameda, CA), and the Joint Medical Research Council/Welcome Trust (Grant No. 099175/Z/12/Z Human Developmental Biology Resource http://hdbr.org), Newcastle upon Tyne, England. We are grateful to Dr Suzie Scales (Genetech) for the Shh antibody, Dr Cliff Tabin (Harvard) for the SHH plasmid and Dr Bill Andrews (UCL) for critical reading of the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval Tissue was obtained from the Human Fetal Tissue Repository at the Albert Einstein College of Medicine (Bronx), Advanced Bioscience Resources (Alameda, CA), StemEx (Diamond Springs, CA, USA) and the joint MRC/Wellcome Trust-funded Human Developmental Biology Resource (http://www.hdbr.org) after legal abortions with informed maternal written consent and approval from the Ethics Committees of the participating institutions. All human material was handled with special care and in accordance with the ethical standards set by the Ethics Committee of the University of Connecticut and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This work was funded by NIH Grants 2R01NS041489 and Subcontract 5R01DA023999-07(NZ).

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Allen BL, Tenzen T, McMahon AP (2007) The Hedgehog-binding proteins Gas1 and Cdo cooperate to positively regulate Shh signaling during mouse development. Genes Dev 21(10):1244–1257. https://doi.org/10.1101/gad.1543607
Komada M, Saitoh H, Kinboshi M, Miura T, Shiota K, Ishibashi M (2008) Hedgehog signaling is involved in development of the neocortex. Development 135(16):2717–2727. https://doi.org/10.1242/dev.015891

Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6(4):312–324. https://doi.org/10.1038/nrn1648

Liu Y, May NR, Fan CM (2001) Growth arrest specific gene 1 is a positive growth regulator for the cerebellum. Dev Biol 236(1):30–45. https://doi.org/10.1006/dbio.2000.0146

Machold R, Hayashi S, Rutlin M, Muzumdar MD, Nery S, Corbin JG, Grilli-Linde A, Dellovade T, Porter JA, Rubin LL, Dudek H, McMahon AP, Fishell G (2003) Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neurogn 39(6):937–950. https://doi.org/10.1016/S0896-6273(03)00561-0

Malik S, Vinukonda G, Vose LR, Diamond D, Bhimavarapu BB, Hu F, Zia MT, Hevner R, Zecevic N, Ballabh P (2013) Neurogenesis continues in the third trimester of pregnancy and is suppressed by premature birth. J Neurosci 33(2):411–423. https://doi.org/10.1523/jneurosci.4445-12.2013

Marigo V, Roberts DJ, Lee SM, Tsukurov O, Levi T, Gastier JM, Malik S, Vinukonda G, Fan CM (2001) Growth arrest specific gene 1 is a positive growth regulator for the cerebellum. Dev Biol 236(1):30–45. https://doi.org/10.1006/dbio.2000.0146

Marigo V, Roberts DJ, Lee SM, Tsukurov O, Levi T, Gastier JM, Epstein DJ, Gilbert DJ, Copeland NG, Seidman CE et al (1995) Cloning, expression, and chromosomal location of SHH and IHH: two human homologues of the Drosophila segment polarity gene hedgehog. Genomics 28(1):44–51

Maroof AM, Keros S, Tyson JA, Ying SW, Ganat YM, Merkle FT, Liu B, Goublurn A, Stanley EG, Elefanty AG, Widmer HR, Eggan K, Goldstein PA, Anderson SA, Stude L (2013) Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell 12(5):559–572. https://doi.org/10.1016/j.stem.2013.04.008

Martinelli DC, Fan CM (2007) Gas1 extends the range of Hedgehog action by facilitating its signaling. Genes Dev 21(10):1231–1243. https://doi.org/10.1101/gad.1546307

McLellan JS, Zheng X, Hauk G, Ghirlando R, Heath PA, Leachy DJ (2008) The mode of Hedgehog binding to Ihog homologues is not conserved among different phyla. Nature 455(7215):979–983. https://doi.org/10.1038/nature07358

Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szaler A, Ebbert A, Riley ZL, Royall JJ, Aiona K, Arnold SA, Muenke MM, Benett C, Bertagnolli D, Brouner K, Butler S, Caldejon S, Carey A, Cuhaciyan C, Dalley BA, Dee N, Doblar EA, Facer BA, Feng D, Fliss TP, Gee G, Goldy J, Gourley L, Gregor BW, Gu G, Howard RE, Jochim MJ, Kuan CL, Lau C, Lee CK, Lee F, Lemon TA, Lesnar P, McMurray MT (2007) Gas1 is a modifier for holoprosencephaly and genetically continues in the third trimester of pregnancy and is suppressed by premature birth. J Neurosci 33(2):411–423. https://doi.org/10.1523/jneurosci.4445-12.2013

Minozzi A, Imaizumi K, Jones KL, Campo MD, Martin RA, Mei-bones M, Neche P, Pierpont ME, Robin NH, Young ID, Roessler E, Muenke M (2012) Missense substitutions in the GAS1 protein present in holoprosencephaly patients reduce the affinity for its ligand, SHH. Hum Genet 131(2):301–310. https://doi.org/10.1007/s00439-011-1078-6

Molla AA, Nowakowski Tomasz J, Chen J, Retallack H, Sandoval-Espinosa C, Nicholas Cory R, Shuga J, Liu Siyuan J, Oldham Michael C, Diaz A, Lim Daniel A, Leyrat Anne A, West Jay A, Kriegstein Arnold R (2015) Molecular Identity of human outer radial glia during cortical development. Cell 163(1):55–67. https://doi.org/10.1016/j.cell.2015.09.004

Radicou NV, Ayoub AE, Memi F, Xu Y, Maroof A, Jakovec iVS, Anderson SA, Rakic P, Zecevic N (2014) Diversity of cortical interneurons in primates: the role of the dorsal proliferative niche. Cell Rep 9(6):2139–2151. https://doi.org/10.1016/j.celrep.2014.11.026

Radicou NV, Memi F, Ortega JA, Glidden N, Zhan H, Zecevic N (2016) The role of sonic hedgehog in the specification of human cortical progenitors in vitro. Cereb cortex 26(1):131–143. https://doi.org/10.1093/cercor/bhu183

Reilly SK, Yin J, Ayoub AE, Emera D, Leng J, Conrey J, Sarro R, Rakic P, Noonan JP (2015) Evolutionary genomics. Evolutionary changes in promoter and enhancer activity during human corticogenesis. Science 347(6226):1155–1159. https://doi.org/10.1126/science.1260943

Ribeiro LA, Quezi GR, Nascimento A, Bertolacini CP, Richieri-Costa A (2010) Holoprosencephaly and holoprosencephaly-like phenotype and GAS1 DNA sequence changes: report of four Brazilian patients. Am J Med Genet A 152A(7):1688–1694. https://doi.org/10.1002/ajmg.a.33466

Santiago G, Abramides DV, De-Vitto LP, Ribeiro LA, Meira SG Jr, Richieri-Costa A (2006) Language skills and neuropsychological performance in patients with SHH mutations and a holoprosencephaly-like phenotype. Am J Med Genet A 140(19):2085–2090. https://doi.org/10.1002/ajmg.a.31311

Selemor LD, Zecevic N (2015) Schizophrenia: a tale of two critical periods for prefrontal cortical development. Transl Psychiatry 5:e623. https://doi.org/10.1038/tp.2015.115

Seppala M, Depew MJ, Martinelli DC, Fan CM, Sharpe PT, Cobourne MT (2007) Gas1 is a modifier for holoprosencephaly and genetically interacts with sonic hedgehog. J Clin Invest 117(6):1575–1584. https://doi.org/10.1172/jci32032

Silbereis JC, Pochareddy S, Zhu Y, Li M, Sestan N (2016) The cellular and molecular landscapes of the developing human central nervous system. Neuron 89(2):248–268. https://doi.org/10.1016/j.neuron.2015.12.008

Tekki-Kessaris N, Woodruff R, Hall AC, Gaffield W, Kimura S, Stiles CD, Rovitch DH, Richardson WD (2001) Hedgehog-dependent oligodendrocyte lineage specification in the telencephalon. Development 128(13):2545–2554

Tennent T, Allen BL, Cole F, Kang JS, Krauss RS, McMahon AP (2006) The cell surface membrane proteins Cdo and Boc are components and targets of the Hedgehog signaling pathway and feedback network in mice. Dev Cell 10(5):647–656. https://doi.org/10.1016/j.devcel.2006.04.004

Tyson JA, Goldberg EM, Maroof AM, Xu Q, Peters TJ, Anderson SA (2015) Duration of culture and sonic hedgehog signaling differentially specify PV versus SST cortical interneuron fates from...
embryonic stem cells. Development 142(7):1267–1278. https://doi.org/10.1242/dev.111526
Wang L, Hou S, Han YG (2016a) Hedgehog signaling promotes basal progenitor expansion and the growth and folding of the neocortex. Nat Neurosci 19(7):888–896 https://doi.org/10.1038/nn.4307
Wang Y, Wu Q, Yang P, Wang C, Liu J, Ding W, Liu W, Bai Y, Yang Y, Wang H, Gao S, Wang X (2016b) LSD1 co-repressor Rcor2 orchestrates neurogenesis in the developing mouse brain. Nat Commun 7:10481. https://doi.org/10.1038/ncomms10481
Xu Q, Wonders CP, Anderson SA (2005) Sonic hedgehog maintains the identity of cortical interneuron progenitors in the ventral telencephalon. Development 132(22):4987–4998. https://doi.org/10.1242/dev.02090
Yam PT, Langlois SD, Morin S, Charron F (2009) Sonic hedgehog guides axons through a noncanonical, Src-family-kinase-dependent signaling pathway. Neuron 62(3):349–362. https://doi.org/10.1016/j.neuron.2009.03.022
Zhang W, Kang JS, Cole F, Yi MJ, Krauss RS (2006) Cdo functions at multiple points in the sonic hedgehog pathway, and Cdo-deficient mice accurately model human holoprosencephaly. Dev cell 10(5):657–665. https://doi.org/10.1016/j.devcel.2006.04.005